Summary

The Global Cell Reprogramming Market was valued at USD 325.45 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.14% through 2030. Cell reprogramming has emerged as a revolutionary field in biotechnology and regenerative medicine. It holds the promise of transforming ordinary cells into pluripotent stem cells or directly converting one cell type into another, offering unprecedented opportunities for disease modeling, drug discovery, and regenerative therapies. The global cell reprogramming market has been steadily growing, driven by advancements in technology, increasing research funding, and a growing demand for innovative healthcare solutions.
Cell reprogramming involves the conversion of mature, specialized cells into a more primitive state, often akin to embryonic stem cells. This process can be achieved through various techniques, with the most well-known being induced pluripotent stem cell (iPSC) reprogramming and direct lineage conversion. iPSC reprogramming allows scientists to take adult cells and rewind their developmental clock, making them pluripotent and capable of differentiating into various cell types. In contrast, direct lineage conversion skips the pluripotent stage, directly converting one cell type into another, such as turning skin cells into neurons.
The global cell reprogramming market is driven by a diverse range of applications. Cell reprogramming has the potential to revolutionize regenerative medicine by enabling the creation of patient-specific, functional cells for transplantation, thereby reducing the risk of rejection. Researchers can use pluripotent stem cell to create disease-specific cell lines, allowing them to study the molecular mechanisms of various diseases and screen potential drug candidates. Cell reprogramming plays a crucial role in drug screening and toxicity testing, reducing the need for animal testing and accelerating drug development. Pluripotent stem cell can be generated from individual patients, enabling the development of personalized therapies and treatment plans.
Key Market Drivers
Rising Prevalence of Chronic Diseases is Driving the Global Cell Reprogramming Market
The global healthcare landscape is witnessing a paradigm shift as chronic diseases continue to rise in prevalence. Diseases such as diabetes, cardiovascular disorders, neurodegenerative conditions, and cancer have become increasingly common, posing a significant challenge to healthcare systems worldwide. In response to this growing health crisis, the field of cell reprogramming is emerging as a promising frontier for addressing chronic diseases. The global cell reprogramming market is gaining momentum as researchers and biotechnology companies explore innovative ways to harness the regenerative potential of cells. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments.
Key Market Challenges
Technical Complexity
One of the primary challenges in the field of cell reprogramming is the technical complexity involved in generating high-quality iPSCs. Reprogramming adult cells into pluripotent stem cells is a delicate process that requires precise manipulation of cellular factors. Researchers must carefully select reprogramming methods, optimize culture conditions, and monitor cell differentiation to ensure the reliability and safety of iPSCs. This technical complexity not only demands considerable expertise but also makes the production of iPSCs time-consuming and costly.
Key Market Trends
Technological Advancements
The field of regenerative medicine has been revolutionized in recent years, thanks to significant advancements in cell reprogramming technology. Cell reprogramming, a process that involves resetting the identity of mature cells to a pluripotent state, has opened new avenues for the treatment of various diseases and the development of personalized medicine. As technological innovations continue to accelerate, the global cell reprogramming market is experiencing unprecedented growth. The advent of CRISPR-Cas9 technology has significantly enhanced the precision and efficiency of cell reprogramming. Researchers can now edit specific genes within cells, eliminating potential genetic mutations that may hinder the successful reprogramming process. This innovation has accelerated the production of high-quality iPSCs for various applications.
Automation systems and high-throughput screening platforms have streamlined the cell reprogramming process. This allows for the rapid generation of iPSCs in larger quantities, making them more accessible for research and clinical use. Automated systems also reduce the risk of contamination and human error, ensuring consistent and reliable results. Technological advancements in 3D bioprinting and the development of organoids have expanded the possibilities of cell reprogramming. These techniques enable the creation of complex, tissue-like structures from iPSCs, paving the way for more advanced disease modeling and drug testing. Artificial intelligence and machine learning algorithms have become integral in analyzing and interpreting large datasets generated from cell reprogramming experiments. These tools help identify novel factors and pathways involved in reprogramming, leading to more efficient and targeted approaches. Traditional methods of introducing reprogramming factors into cells often relied on viral vectors, which carried risks of genomic integration and mutagenesis. Non-viral delivery systems, such as synthetic RNA and protein-based approaches, have emerged as safer alternatives, improving the overall safety profile of cell reprogramming.
The global cell reprogramming market is witnessing remarkable growth, driven by these technological advancements and their applications. Pharmaceutical companies are increasingly investing in iPSC-based drug discovery and toxicity testing, while academic institutions are using iPSCs to study various diseases, including neurodegenerative disorders, heart disease, and cancer. Furthermore, the field of regenerative medicine is moving closer to the realization of personalized therapies. iPSCs derived from a patient's own cells can be reprogrammed and differentiated into specific cell types, offering the potential for individualized treatments and reduced risk of immune rejection.
Key Market Players
• Allele Biotechnology co. ltd.
• ALSTEM, INC
• Applied Biological Materials Inc.
• Axol Bioscience Ltd.
• Fujifilm Cellular Dynamics inc.
• Lonza Group AG
• Mogrify inc.
• REPROCELL Inc.
• Stemnovate Limited
• Thermo Fisher Scientific Inc
Report Scope:
In this report, the Global Cell Reprogramming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Cell Reprogramming Market, By Technology:
o Sendai Virus-based
o mRNA Reprogramming
o Others
• Cell Reprogramming Market, By Application:
o Research
o Therapeutic
• Cell Reprogramming Market, By End user:
o Research & Academic Institutes
o Biotechnology & Pharmaceutical Companies
o Hospitals & Clinics
o Others
• Cell Reprogramming Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Cell Reprogramming Market.
Available Customizations:
Global Cell Reprogramming market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Cell Reprogramming Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Sendai Virus-based, mRNA Reprogramming, Others)
5.2.2. By Application (Research, Therapeutic)
5.2.3. By End user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, Others)
5.2.4. By Region
5.2.5. By Company (Shares of Top 5 Market Players, 2024)
5.3. Market Map
5.3.1. By Technology
5.3.2. By Application
5.3.3. By End user
5.3.4. By Region
6. North America Cell Reprogramming Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By End user
6.2.4. By Country
6.2.4.1. United States Cell Reprogramming Market Outlook
6.2.4.1.1. Market Size & Forecast
6.2.4.1.1.1. By Value
6.2.4.1.2. Market Share & Forecast
6.2.4.1.2.1. By Technology
6.2.4.1.2.2. By Application
6.2.4.1.2.3. By End user
6.2.4.2. Canada Cell Reprogramming Market Outlook
6.2.4.2.1. Market Size & Forecast
6.2.4.2.1.1. By Value
6.2.4.2.2. Market Share & Forecast
6.2.4.2.2.1. By Technology
6.2.4.2.2.2. By Application
6.2.4.2.2.3. By End user
6.2.4.3. Mexico Cell Reprogramming Market Outlook
6.2.4.3.1. Market Size & Forecast
6.2.4.3.1.1. By Value
6.2.4.3.2. Market Share & Forecast
6.2.4.3.2.1. By Technology
6.2.4.3.2.2. By Application
6.2.4.3.2.3. By End user
7. Europe Cell Reprogramming Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By End user
7.2.4. By Country
7.2.4.1. France Cell Reprogramming Market Outlook
7.2.4.1.1. Market Size & Forecast
7.2.4.1.1.1. By Value
7.2.4.1.2. Market Share & Forecast
7.2.4.1.2.1. By Technology
7.2.4.1.2.2. By Application
7.2.4.1.2.3. By End user
7.2.4.2. Germany Cell Reprogramming Market Outlook
7.2.4.2.1. Market Size & Forecast
7.2.4.2.1.1. By Value
7.2.4.2.2. Market Share & Forecast
7.2.4.2.2.1. By Technology
7.2.4.2.2.2. By Application
7.2.4.2.2.3. By End user
7.2.4.3. United Kingdom Cell Reprogramming Market Outlook
7.2.4.3.1. Market Size & Forecast
7.2.4.3.1.1. By Value
7.2.4.3.2. Market Share & Forecast
7.2.4.3.2.1. By Technology
7.2.4.3.2.2. By Application
7.2.4.3.2.3. By End user
7.2.4.4. Italy Cell Reprogramming Market Outlook
7.2.4.4.1. Market Size & Forecast
7.2.4.4.1.1. By Value
7.2.4.4.2. Market Share & Forecast
7.2.4.4.2.1. By Technology
7.2.4.4.2.2. By Application
7.2.4.4.2.3. By End user
7.2.4.5. Spain Cell Reprogramming Market Outlook
7.2.4.5.1. Market Size & Forecast
7.2.4.5.1.1. By Value
7.2.4.5.2. Market Share & Forecast
7.2.4.5.2.1. By Technology
7.2.4.5.2.2. By Application
7.2.4.5.2.3. By End user
8. Asia Pacific Cell Reprogramming Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By End user
8.2.4. By Country
8.2.4.1. China Cell Reprogramming Market Outlook
8.2.4.1.1. Market Size & Forecast
8.2.4.1.1.1. By Value
8.2.4.1.2. Market Share & Forecast
8.2.4.1.2.1. By Technology
8.2.4.1.2.2. By Application
8.2.4.1.2.3. By Technology
8.2.4.2. India Cell Reprogramming Market Outlook
8.2.4.2.1. Market Size & Forecast
8.2.4.2.1.1. By Value
8.2.4.2.2. Market Share & Forecast
8.2.4.2.2.1. By Technology
8.2.4.2.2.2. By Application
8.2.4.2.2.3. By End user
8.2.4.3. South Korea Cell Reprogramming Market Outlook
8.2.4.3.1. Market Size & Forecast
8.2.4.3.1.1. By Value
8.2.4.3.2. Market Share & Forecast
8.2.4.3.2.1. By Technology
8.2.4.3.2.2. By Application
8.2.4.3.2.3. By End user
8.2.4.4. Japan Cell Reprogramming Market Outlook
8.2.4.4.1. Market Size & Forecast
8.2.4.4.1.1. By Value
8.2.4.4.2. Market Share & Forecast
8.2.4.4.2.1. By Technology
8.2.4.4.2.2. By Application
8.2.4.4.2.3. By End user
8.2.4.5. Australia Cell Reprogramming Market Outlook
8.2.4.5.1. Market Size & Forecast
8.2.4.5.1.1. By Value
8.2.4.5.2. Market Share & Forecast
8.2.4.5.2.1. By Technology
8.2.4.5.2.2. By Application
8.2.4.5.2.3. By End user
9. South America Cell Reprogramming Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Application
9.2.3. By End user
9.2.4. By Country
9.2.4.1. Brazil Cell Reprogramming Market Outlook
9.2.4.1.1. Market Size & Forecast
9.2.4.1.1.1. By Value
9.2.4.1.2. Market Share & Forecast
9.2.4.1.2.1. By Technology
9.2.4.1.2.2. By Application
9.2.4.1.2.3. By End user
9.2.4.2. Argentina Cell Reprogramming Market Outlook
9.2.4.2.1. Market Size & Forecast
9.2.4.2.1.1. By Value
9.2.4.2.2. Market Share & Forecast
9.2.4.2.2.1. By Technology
9.2.4.2.2.2. By Application
9.2.4.2.2.3. By End user
9.2.4.3. Colombia Cell Reprogramming Market Outlook
9.2.4.3.1. Market Size & Forecast
9.2.4.3.1.1. By Value
9.2.4.3.2. Market Share & Forecast
9.2.4.3.2.1. By Technology
9.2.4.3.2.2. By Application
9.2.4.3.2.3. By End user
10. Middle East & Africa Cell Reprogramming Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Application
10.2.3. By End user
10.2.4. By Country
10.2.4.1. South Africa Cell Reprogramming Market Outlook
10.2.4.1.1. Market Size & Forecast
10.2.4.1.1.1. By Value
10.2.4.1.2. Market Share & Forecast
10.2.4.1.2.1. By Technology
10.2.4.1.2.2. By Application
10.2.4.1.2.3. By End user
10.2.4.2. Saudi Arabia Cell Reprogramming Market Outlook
10.2.4.2.1. Market Size & Forecast
10.2.4.2.1.1. By Value
10.2.4.2.2. Market Share & Forecast
10.2.4.2.2.1. By Technology
10.2.4.2.2.2. By Application
10.2.4.2.2.3. By End user
10.2.4.3. UAE Cell Reprogramming Market Outlook
10.2.4.3.1. Market Size & Forecast
10.2.4.3.1.1. By Value
10.2.4.3.2. Market Share & Forecast
10.2.4.3.2.1. By Technology
10.2.4.3.2.2. By Application
10.2.4.3.2.3. By End user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Technology Launches
13. Competitive Landscape
13.1. Allele Biotechnology co. ltd.
13.2. ALSTEM, INC
13.3. Applied Biological Materials Inc.
13.4. Axol Bioscience Ltd.
13.5. Fujifilm Cellular Dynamics inc.
13.6. Lonza Group AG
13.7. Mogrify inc.
13.8. REPROCELL Inc.
13.9. Stemnovate Limited
13.10.Thermo Fisher Scientific Inc.
14. Strategic Recommendations
15. About us & Disclaimer